• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»electroCore

Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears

By Soujanya Ravi on April 7, 2026   Pharma & Biotech  

Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears

electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.

How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury

By Soujanya Ravi on April 1, 2026   Medical Devices & Diagnostics  

How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury

electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes